Five Routes to Market Relevance in AML: Differentiation by Unmet Need
MARKETVUE® REPORT: More than half of STXBP1 Encephalopathy patients experience refractory seizures with currently available antiepileptics
Despite significant unmet need, there are currently no disease-modifying therapies available for the treatment of STXBP1 encephalopathy, although there are at least six assets in preclinical development, according to findings [...]
MARKETVUE® REPORT: Over 80% of Tardive Dyskinesia patients are currently prescribed Austedo or Ingrezza, according to U.S. Neurologists
U.S. physicians report that the majority of their patients on Teva Pharmaceuticals’ Austedo and Neurocrine Biosciences’ Ingrezza achieve some degree of symptom relief, according to findings from REACH Market Research. [...]